- Home
- OVLY vs ACRS Comparison
OVLY vs ACRS Comparison
Compare OVLY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVLY
- ACRS
- Stock Information
- Founded
- OVLY 1990
- ACRS 2012
- Country
- OVLY United States
- ACRS United States
- Employees
- OVLY N/A
- ACRS N/A
- Industry
- OVLY Major Banks
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- OVLY Finance
- ACRS Health Care
- Exchange
- OVLY Nasdaq
- ACRS Nasdaq
- Market Cap
- OVLY 219.0M
- ACRS 198.2M
- IPO Year
- OVLY N/A
- ACRS 2015
- Fundamental
- Price
- OVLY $27.65
- ACRS $2.34
- Analyst Decision
- OVLY
- ACRS Strong Buy
- Analyst Count
- OVLY 0
- ACRS 9
- Target Price
- OVLY N/A
- ACRS $9.25
- AVG Volume (30 Days)
- OVLY 8.9K
- ACRS 1.3M
- Earning Date
- OVLY 10-22-2025
- ACRS 11-06-2025
- Dividend Yield
- OVLY 2.16%
- ACRS N/A
- EPS Growth
- OVLY N/A
- ACRS N/A
- EPS
- OVLY 2.84
- ACRS N/A
- Revenue
- OVLY $79,783,000.00
- ACRS $16,789,000.00
- Revenue This Year
- OVLY N/A
- ACRS N/A
- Revenue Next Year
- OVLY N/A
- ACRS N/A
- P/E Ratio
- OVLY $9.74
- ACRS N/A
- Revenue Growth
- OVLY 2.98
- ACRS N/A
- 52 Week Low
- OVLY $22.70
- ACRS $1.05
- 52 Week High
- OVLY $32.24
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- OVLY 54.85
- ACRS 63.26
- Support Level
- OVLY $25.41
- ACRS $2.10
- Resistance Level
- OVLY $27.03
- ACRS $2.51
- Average True Range (ATR)
- OVLY 0.55
- ACRS 0.18
- MACD
- OVLY 0.15
- ACRS 0.04
- Stochastic Oscillator
- OVLY 83.90
- ACRS 77.92
About OVLY Oak Valley Bancorp (CA)
Oak Valley Bancorp is a bank holding company that operates through Oak Valley Community Bank (the Bank). The Bank offers a complement of business checking and savings accounts for its business customers. The Bank also offers commercial and real estate loans, as well as lines of credit. In addition, the bank provides other services for both individuals and businesses including online banking, remote deposit capture, mobile banking, merchant services, night depository, extended hours, wire transfer of funds, note collection, and automated teller machines in a national network. Its primary source of revenue is net interest income.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.